Cargando…
Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of prod...
Autores principales: | Haluzík, Martin, Flekač, Milan, Lengyel, Csaba, Taybani, Zoltán, Guja, Cristian, Mihai, Bogdan-Mircea, Cerghizan, Anca, Martinka, Emil, Kovacs, Gabor, Kempler, Péter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136377/ https://www.ncbi.nlm.nih.gov/pubmed/32144742 http://dx.doi.org/10.1007/s13300-020-00777-2 |
Ejemplares similares
-
Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro)
por: Bala, Cornelia, et al.
Publicado: (2022) -
Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis
por: Haluzík, Martin, et al.
Publicado: (2023) -
Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes
por: Kis, János Tibor, et al.
Publicado: (2021) -
Improving Type 2 Diabetes Management in General Practice Using a Second-Generation Basal Insulin Analogue Insulin Glargine 300 U/mL: A Practical Guide
por: Deed, Gary, et al.
Publicado: (2019) -
Expert Opinion: A Call for Basal Insulin Titration in Patients with Type 2 Diabetes in Daily Practice: Southeast European Perspective
por: Hancu, Nicolae, et al.
Publicado: (2021)